Going after Vicodin: biotech KemPharm files for a $58 million IPO

KemPharm, which is developing an abuse-deterrent version of Vicodin, filed on Wednesday with the SEC to raise up to $58 million in an initial public offering.

The Coralville, IA-based company, which was founded in 2006, plans to list on the NASDAQ under the symbol KMPH. KemPharm initially filed confidentially on December 19, 2014. Cowen & Company and RBC Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.